Oncology
Glioblastoma Remission Rates Remain Challenging Despite Treatment Advances
Only 25% of glioblastoma patients experience remission lasting at least two years, highlighting the urgent need for improved treatments for this aggressive brain cancer.
Lantern Pharma Reports Complete Response in AI-Driven Cancer Drug Trial
Lantern Pharma's AI-developed drug LP-284 achieved a complete metabolic response in a heavily pre-treated lymphoma patient, demonstrating the potential of artificial intelligence to accelerate oncology drug development and address critical treatment gaps.
Oncotelic's Nanomedicine Platform Advances Cancer Treatment Through Enhanced Drug Delivery
Oncotelic Therapeutics' Deciparticle platform represents a significant advancement in nanomedicine that improves drug bioavailability and therapeutic effectiveness in oncology treatments.
Nanomedicine Breakthroughs Transform Cancer Drug Delivery and Bioavailability
Recent advancements in nanomedicine technology are revolutionizing oncology treatment by improving drug delivery systems, enhancing bioavailability, and potentially transforming underperforming cancer drugs into effective therapies through platforms like Oncotelic Therapeutics' Deciparticle.
Study Reveals Chemotherapy May Damage Brain's Waste Drainage System, Explaining 'Chemo Brain' Symptoms
New research identifies chemotherapy-induced damage to the brain's waste drainage network as a potential cause of cognitive difficulties affecting up to 75% of cancer patients during and after treatment.
Lantern Pharma to Present AI-Driven Oncology Pipeline at ThinkEquity Conference
Lantern Pharma will present its AI-powered cancer drug development platform and pipeline at the ThinkEquity Conference, highlighting how artificial intelligence is transforming oncology research and potentially delivering life-changing therapies to patients worldwide.
New Melanoma Test Shows Three-Fold Improvement in Predicting Lymph Node Metastasis Risk
The Merlin CP-GEP test accurately stratifies melanoma patients by sentinel node metastasis risk, potentially reducing unnecessary surgical procedures through improved personalized care.
Oncotelic Therapeutics Announces Three Abstracts on Deciparticle Everolimus Accepted for 2025 San Antonio Breast Cancer Symposium
Oncotelic Therapeutics will present three abstracts on its investigational intravenous Deciparticle everolimus at the 2025 San Antonio Breast Cancer Symposium, highlighting potential improvements over existing mTOR inhibitors for metastatic breast cancer treatment.
Kairos Pharma Reports Positive Interim Phase 2 Results for ENV-105 in Advanced Prostate Cancer
Kairos Pharma announced positive interim Phase 2 data showing ENV-105 combined with apalutamide achieved clinical benefit in 86% of metastatic castration-resistant prostate cancer patients, potentially addressing treatment resistance in advanced disease.
Oncotelic Therapeutics Fills Critical Gaps in Cancer Treatment with RNA and Small-Molecule Therapies
Oncotelic Therapeutics is developing innovative RNA therapeutics and small-molecule drugs to address unmet needs in rare pediatric cancers and resistant solid tumors where traditional treatments have fallen short.
Digital Tumor Twins Promise Personalized Brain Cancer Treatment Breakthrough
Cedars-Sinai is developing virtual brain tumor replicas that could revolutionize cancer treatment by predicting tumor growth and therapy responses, potentially improving outcomes for patients with difficult-to-treat cancers like glioblastoma.
TransCode Therapeutics Advances Cancer Treatment with Successful Phase 1a Trial of TTX-MC138
TransCode Therapeutics has successfully completed Phase 1a clinical trials for TTX-MC138, an RNA-based cancer treatment targeting metastatic disease, showing promising safety results and disease stabilization in nearly half of patients, advancing to Phase 2 evaluation.
Harvard AI System Revolutionizes Brain Tumor Diagnosis During Surgery
Harvard Medical School researchers have developed an AI tool called PICTURE that achieves 99.8% accuracy in distinguishing between glioblastoma and primary central nervous system lymphoma during surgery, potentially transforming treatment outcomes for brain cancer patients.
Lantern Pharma Executives Discuss AI's Potential to Transform CNS Oncology Drug Development
Lantern Pharma's leadership explores how artificial intelligence can significantly reduce the time and cost of developing central nervous system cancer treatments, potentially accelerating patient access to new therapies.
Glioblastoma Found to Erode Skull Tissue, Challenging Long-Held Treatment Assumptions
A recent study reveals that glioblastoma, the deadliest form of brain cancer, erodes patients' skulls, challenging the long-held assumption that the disease is localized and potentially explaining why current therapies have shown dismal success rates.
Soligenix Expands European Medical Advisory Board to Advance CTCL Treatment Development
Soligenix is strengthening its European medical advisory board and advancing Phase 3 clinical trials for HyBryte, a potential new treatment for cutaneous T-cell lymphoma that addresses significant unmet medical needs in European patients.
Oncotelic's Injectable Everolimus Shows Promise for Dramatically Improved Breast Cancer Treatment
Oncotelic Therapeutics has received clearance to begin Phase 1 clinical trials for Sapu003, an injectable form of Everolimus that could increase drug bioavailability from 10% to up to 100%, potentially transforming breast cancer treatment efficacy.
TransCode Therapeutics Acquires Polynoma, Secures $25 Million Investment to Advance Oncology Pipeline
TransCode Therapeutics has acquired Polynoma and secured $25 million from CK Life Sciences to advance its Phase 2 trial of TTX-MC138 and Phase 3-ready melanoma vaccine seviprotimut-L, positioning the company to deliver meaningful therapeutic advances for patients battling melanoma and metastatic disease.
New Research Identifies Key Mechanism Behind Cancer Immunotherapy Failures
Ohio State University researchers have discovered a previously unknown stress pathway that explains why immunotherapy fails in most cancer patients, potentially paving the way for more effective treatments.
Oncotelic Therapeutics Announces Phase 1 Trial Enrollment for Novel Intravenous Everolimus Formulation in Australia
Oncotelic Therapeutics has opened enrollment for the first clinical trial of Sapu-003, an intravenous Deciparticle formulation of everolimus that represents a significant advancement in mTOR-targeted cancer therapy delivery for patients with advanced breast cancer and other malignancies.
Soligenix Expands European Medical Advisory Board to Advance Cutaneous T-Cell Lymphoma Treatment
Soligenix Inc. has expanded its European Medical Advisory Board to guide the confirmatory Phase 3 trial of HyBryte for early-stage cutaneous T-cell lymphoma, strengthening European engagement ahead of potential commercialization of this novel photodynamic therapy.
Scorpion Venom Compound Shows Promise in Brain Cancer Treatment Research
Researchers are exploring how scorpion venom compounds could revolutionize brain tumor treatment by helping the immune system target glioblastoma more effectively.
Soligenix Advances HyBryte Treatment for Cutaneous T-Cell Lymphoma with FLASH Trial Results
Soligenix is strengthening its position in CTCL treatment through promising results from its HyBryte FLASH studies, representing significant progress toward establishing a new standard of care in an underserved therapeutic area.
Circular DNA Fragments Identified as Key Factor in Glioblastoma Lethality
International researchers have discovered that rogue circular DNA fragments operating independently from chromosomes may explain why glioblastoma remains so deadly despite medical advances, potentially opening new treatment pathways.
Oncotelic Therapeutics CEO Outlines Key Clinical Milestones in BioMedWire Podcast Interview
Oncotelic Therapeutics CEO Dr. Vuong Trieu discussed the company's upcoming clinical and regulatory milestones in oncology and rare disease treatments during a recent podcast appearance, highlighting potential catalysts for investor attention.
Lantern Pharma Completes Japan Enrollment in Phase 2 Trial for Never-Smoker Lung Cancer Treatment
Lantern Pharma has achieved targeted patient enrollment in Japan for its Phase 2 HARMONIC trial evaluating LP-300 in never-smoker non-small cell lung cancer patients, marking significant progress in addressing an underserved population with high unmet medical need.
Oncotelic Therapeutics Advances Late-Stage Oncology Pipeline Under Proven Leadership
Oncotelic Therapeutics is progressing multiple late-stage clinical programs in high-unmet-need oncology indications under CEO Dr. Vuong Trieu, whose track record with blockbuster cancer drugs positions the company for potential therapeutic breakthroughs.
Oncotelic Therapeutics CEO's Patent Portfolio and Track Record Position Company for Oncology Market Growth
Oncotelic Therapeutics' CEO Dr. Vuong Trieu, developer of Abraxane, brings extensive patent expertise and successful drug development experience that strengthens the company's position in advancing innovative cancer therapies with significant market potential.
Plus Therapeutics Subsidiary CNSide Diagnostics Achieves CLIA Accreditation for CNS Cancer Testing Lab
CNSide Diagnostics has received CMS accreditation for its clinical laboratory, enabling broader patient access and insurance coverage for its cerebrospinal fluid assay platform used in central nervous system cancer detection.
Dietary Protein Restriction May Enhance Glioblastoma Treatment Efficacy, Study Finds
University of Michigan research indicates that low-protein diets combined with serine-free protein shakes could improve chemotherapy and radiation outcomes for glioblastoma patients by making tumors more vulnerable to treatment.